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ABSTRACT 
 One potential physiological target for new antischistosomals is the parasite's system for 
excretion of wastes and xenobiotics. P-glycoprotein (Pgp), a member of the ATP-binding 
cassette superfamily of proteins, is an ATP-dependent efflux pump involved in transport of 
toxins and xenobiotics from cells. In vertebrates, increased expression of Pgp is associated with 
multidrug resistance in tumor cells. Pgp may also play a role in drug resistance in helminths. In 
this report, we examine the relationship between praziquantel (PZQ), the current drug of choice 
against schistosomiasis, and Pgp expression in Schistosoma mansoni. We show that levels of 
RNA for SMDR2, a Pgp homolog from S. mansoni, increase transiently in adult male worms 
following exposure to sublethal concentrations (100 - 500 nM) of PZQ. A corresponding, though 
delayed, increase in anti-Pgp immunoreactive protein expression occurs in adult males following 
exposure to PZQ.  The level of anti-Pgp immunoreactivity in particular regions of adult worms 
also increases in response to PZQ. Adult worms from an Egyptian S. mansoni isolate with 
reduced sensitivity to PZQ express increased levels of SMDR2 RNA and anti-Pgp-
immunoreactive protein, perhaps indicating a role for multidrug resistance proteins in 
development or maintenance of PZQ resistance. 
Keywords: Schistosoma mansoni, P-glycoprotein, multidrug resistance, praziquantel, ABC 
transporter 
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INTRODUCTION 
 Trematode flatworms of the genus Schistosoma are the causative agents of 
schistosomiasis, a major tropical parasitic disease. Adult schistosomes reside in the blood vessels 
of the host, where, among other functions, they must take up nutrients and dispose of toxic 
metabolites.  
 The current drug of choice against schistosomiasis is praziquantel (PZQ), a 
pyrazinoisoquinoline anthelmintic that is active against all schistosome species, shows minimal 
side effects, and is also effective against other trematode and cestode infections [1-4]. Indeed, 
because of these advantages over other chemotherapeutics, PZQ has in recent years become 
effectively the only antischistosomal commercially available [5,6], making the prospect of 
emerging resistance to PZQ particularly troubling [7].   
The export of biomolecules, including metabolite disposal, is commonly performed by 
members of the ATP-binding-cassette (ABC) superfamily of proteins. One of the members of 
this class, P-glycoprotein (Pgp), is an ATP-dependent efflux pump that in vertebrates serves as 
one of a set of major membrane transporters for toxic and xenobiotic compounds. Pgp is the 
product of the multidrug-resistance 1 (MDR1, ABCB1) gene, which is amplified and 
overexpressed in certain mammalian tumor cells that show broad drug resistance [8-11]. Pgp 
expression levels and allele frequencies are also altered in anthelmintic-resistant populations of 
nematodes [13-18], and the potential roles of Pgp in parasite drug resistance and as a possible 
site for pharmacological modulation in helminths have recently been reviewed [19-21]. 
 Investigation of schistosome and platyhelminth Pgps and other drug transporters has been 
limited. Several years ago, two S. mansoni cDNAs coding for ABC proteins were cloned and 
sequenced [22]. One of these cDNAs (SMDR2) encodes a Pgp-like protein, with 12 
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transmembrane regions and two ATP-binding domains predicted. A partial ABC transporter 
sequence from the liver fluke, Fasciola hepatica has also been reported [23]. Sato et al [24, 25] 
have used fluorescent substrates of Pgp and multidrug resistance-like proteins (MRPs) to 
visualize the excretory system of S. mansoni. They also used compounds known to inhibit these 
transporter activities in mammals to perturb excretory function in schistosomes. PZQ has 
dramatic effects on excretion of resorufin, a likely Pgp substrate [26]. Thus, schistosome 
excretory activity, which is probably mediated by a Pgp-like molecule such as SMDR2, can be 
altered by PZQ, as well as other pharmacological and environmental agents. Furthermore, PZQ 
has been shown [27] to be an inhibitor of Pgp-mediated [3H]-taxol transport in a human intestinal 
epithelial cell line, with a Kiapp = 20 μM (the Kiapp value represents the extracellular 
concentration of test compound bringing about 50% inhibition of active transport; unlike an IC50 
value, it is independent of the affinity and concentration of the reference substrate). 
 Here, we examine the relationship between PZQ and schistosome Pgp in more detail, by 
examining the expression patterns of SMDR2 RNA and anti-Pgp immunoreactive protein in 
response to PZQ. We find that exposure of adult schistosomes to a sub-lethal concentration of 
PZQ results in transiently increased expression of the SMDR2 transcript as well as a ~140 kDa 
band that is immunolabeled by a monoclonal antibody against conserved epitopes of Pgp. In 
addition, we show that adults from EE2, an Egyptian S. mansoni isolate with reduced 
susceptibility to PZQ [28], expresses significantly higher levels of SMDR2 RNA and anti-Pgp 
immunoreactive protein than adults from control, PZQ-sensitive strains.  
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MATERIALS AND METHODS 
Reagents 
 Praziquantel (Sigma) was dissolved in dimethyl sulfoxide for stock solutions, which were 
subsequently diluted to an appropriate concentration in culture media. The mouse monoclonal 
antibody against Pgp [29] was from Abcam (C219). The anti-rabbit tubulin antibody was from 
Santa Cruz Biotechnology (H-235).  
Isolation and treatment of adult schistosomes 
 Female Swiss Webster mice infected with S. mansoni (NMRI strain) were obtained from 
the NIAID Schistosomiasis Resource Center at the Biomedical Research Institute in Rockville, 
MD. Adult S. mansoni were collected by perfusion, as described [30], and maintained in RPMI 
(Invitrogen) plus 10% FBS (Sigma) at 37°C and 5% CO2. Following an overnight incubation, 
worms were exposed to PZQ for variable periods and at different concentrations. In some 
experiments, the mixed worm population was separated into male and female groups, and then 
exposed to PZQ  for various time points. Following incubation, adults were either used for RNA 
and protein extraction immediately, or quick-frozen in liquid nitrogen and stored at -80°C until 
use. Both the EE2 and CD1 worms were obtained from the Theodor Bilharz Research Institute, 
Giza, Egypt. EE2 worms were originally isolated from Egyptian patients not cured following 
three successive doses of PZQ. These worms were also shown to exhibit an approximately three-
fold reduction in PZQ susceptibility when tested in murine infections [31] as well as reduced 
susceptibility to PZQ in vitro [28]. Subsequently, following maintenance of the EE2 isolate over 
several years and through multiple laboratory life cycles without exposure to PZQ, EE2 worms 
continued to exhibit approximately three-fold reduced susceptibility to PZQ compared to PZQ-
susceptible worms [32]. The PZQ-susceptible CD1 isolate has been maintained at the Theodor 
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Bilharz Research Institute, Giza, Egypt for more than two decades, and has not knowingly been 
in contact with PZQ. These adult worms were recovered by perfusion, placed in RNAlater 
(Ambion), and stored first at room temperature and then at -20°C until use. 
RNA extractions and RT-PCR 
 RNA was extracted from adult schistosomes using either RNAqueous-4-PCR (Ambion) 
or the PARIS miRVANA kit (Ambion) using the manufacturer's instructions. All RNA 
preparations were treated with either DNAase 1 or Turbo-DNAase (Ambion) and DNAase 
Inactivation Reagent (Ambion) prior to reverse transcription. Equal amounts of total RNA from 
each sample were primed with 500 ng random hexamers (Promega) and were reverse-transcribed 
using SuperScript II reverse transcriptase (Invitrogen) at 42° for 1 h. Sequences of interest were 
amplified from the cDNA using GoTaq Green Master Mix (Promega), which contains 200 μM 
dNTPs and 1.5 mM MgCl2 in the final reaction, with primers added to 10 μM. Alternatively, 
one-step RT-PCR (Reverse-it 1-step RT-PCR kit, ABgene) was used to amplify the sequences. 
Primers used for amplification of SMDR2 were: SMDR2 RT1 (5′-
GGAGTCGCTGCAGGACGTTTAACT-3′; SMDR RT2 (5′-
AGTGCACCAGGTCGATTGTCAGAT-3′); SMDR2-1 (5′-CCTATGGTGATAATAGTCGGA-
3′); and SMDR2-2 (5′-CGATGTGCAATTATAATAGAATG-3′). Primers used for amplification 
of 18S ribosomal RNA were: 18S-1 (5′-TTAACGAGGACCAATTGGAGGG-3′; and 18S-2 (5′-
CCCCGTCTGTCCCTCTTAACCA-3′). Following a 1 min hot start at 94°C, PCR conditions 
were as follows: 94°C for 30 sec, 50°C for 30 sec, 72°C for 1 min, with the appropriate number 
of cycles determined empirically. Band intensities were quantified using Quantity One software 
(BioRad). 
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Real-time RT-PCR 
 Real-time PCR using SYBR Green was performed using the Brilliant SYBR Green 
QPCR Reagent kit (Statagene) on an Opticon 2 Real-Time PCR Detection System (BioRad). S. 
mansoni glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a reference 
sequence in these experiments. Primers used for amplification of SMDR2 were: SmMDR2-Sy1 
(5′-TGCTCTAGTCGGTTCTAGTGGTTCTG-3′) and SmMDR2-Sy2 (5′-
GCATTAGCTTTGATGGCAGCTTCG-3′). Primers used for amplification of GAPDH cDNA 
were SmGAPDH-1 (5′-AATTATGGCGAGATGGCCGT-3′) and SmGAPDH-2 (5′-
TTTGGCAGCACCAGTGGAA-3′). Following optimization experiments, PCR cycles were set 
as follows: 95°C 3 min, 95°C 30 s, 56.0°C 1 min, 45 cycles performed total, with a melting curve 
from 52°C-95°C included.  
 Real time PCR using Taqman probes was performed with either iQSupermix iSCript 
Reverse transcriptase for One step RT-PCR (Biorad), or the TaqMan One-Step RT-PCR kit 
(Applied Biosystems). S. mansoni 18S ribosomal RNA gene and GAPDH  were used as 
reference sequences in these experiments. Primers used for amplification of SMDR2 were 
SMDR2-TM-F1 (5′-TCTGACAATCGACCTGGTG-3′) and SMDR2-TM-R1 (5′-
CCAAGGAAGCAATGACTAAAAC-3′), and the probe was: 5′FAM-
ACTGCATTTCTGTCCACAGATGCTTC-3′BHQ1. Primers used for amplification of GAPDH 
were: GAPDH-TM-F1 (5′-GCACTCATTTACGGCTACAC-3′) and GAPDH-TM-R1 (5′-
GCTGGAATGACTTTTCCCAC-3′), with 5′HEX-    
ACCATCCTCAAAATTATGGCGAGATGGC-3′BHQ1 as the probe. Primers used for 
amplification of 18S RNA were: Sm-18S-TM-1 (5′-AGGAATTGACGGAAGGGCAC-3′) and 
Sm-18S-TM-2 (5′-ACCACCCACCGAATCAAGAAAG-3′), with 5′HEX-
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AGCCTGCGGTTTAATTCGACTCAACACGG-3′BHQ1 as the probe. PCR cycles were as 
follows: 50°C 10 min, 95°C 5 min., 95°C 13 min, 56°C 30min, with 45 cycles performed total. 
Experiments were performed on either an Opticon 2 Real-Time PCR Detection System (BioRad) 
or an Applied Biosystems 7500 Fast system.  The templates for those experiments using CD1 
and EE2 were amplified, adapter-ligated cDNA pools made from CD1 and EE2 total RNA. 
These cDNA samples were made using primers and protocols of Matz Method B [33]. 
Quantitative analysis of expression levels using this approach have been validated using "virtual 
northern blots", and accurately reflect differential RNA expression patterns [34]. An equal 
amount of RNA from the two isolates was reverse-transcribed and amplified by PCR using 
Superscript II (Invitrogen) and the adapter-primers described in [33], and amplified by PCR. 
These cDNA pools were diluted 1:50 in water prior to use as templates for real time PCR 
experiments. 
 Analysis of real time RT-PCR data was carried out using the 2-ΔΔCt method, with 
appropriate calibrators and corrections for amplification efficiency, as described [35]. A one 
sample t-test was used to determine statistically significant differences from a value of 1 (P ≤ 
0.05), which would indicate no change in expression. Data are presented as mean ± SEM. 
Protein extraction and analysis 
 Protein was extracted using the PARIS miRVANA kit (Ambion) using the manufacturer's 
instructions. Additionally, a protease inhibitor mix (Sigma) was added to the cell disruption 
buffer. Protein concentrations were determined using the Bio-Rad Protein assay (Bio-rad). Equal 
amounts of protein were loaded onto NuPage 4-12 % Bis-Tris gradient gels (Invitrogen), 
transferred to nitrocellulose at 30 V for 1 h, and reversibly stained using Memcode Reversible 
Protein Stain kit (Pierce). The membrane was blocked in 5% dry milk dissolved in phosphate-
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buffered saline containing 0.1% Tween 20 (PBST) at 4°C overnight. Blots were incubated with 
primary antibody for 2 h. at room temperature in 5% dry milk-PBST. Anti-mouse-Pgp (Abcam) 
was used at a 1:1000 dilution and anti-rabbit tubulin at a 1:200 dilution. Following three washes 
in PBS, blots were incubated in either peroxidase-conjugated goat anti- mouse IgG (1:10,000, 
Jackson ImmunoResearch) or goat anti-rabbit IgG (1:10,000, Jackson ImmunoResearch). Blots 
were then washed three times in PBS, incubated in Supersignal West Pico Chemiluminescent 
Substrate (Pierce) for 5 min., and exposed to CL-Xposure film X-ray film (Pierce). Band 
intensities were quantified using either Quantity One (BioRad) or Scion Image (Scioncorp) 
software. 
Immunostaining: 
 Adult S. mansoni (NMRI strain) were exposed for 18 hours in culture to either PZQ (100 
nM) or control RPMI prior to fixation in 4% (w/v) paraformaldehyde in PBS for 1 hr. Worms 
were washed 6 times in 0.1 M PBS, pH 7.4, containing 0.1% (w/v) Triton X-100, 1% (w/v) BSA, 
and 0.1% NaN3 [36]. Schistosomes were incubated in the anti-mouse Pgp monoclonal antibody 
at a 1:40 dilution for 96 hr. at 4° C. Following an overnight wash, worms were treated with goat 
anti-mouse IgG-Rhodamine (Jackson ImmunoResearch; 1:200) for 48 hrs., washed, and mounted 
with PBS/glycerol. Controls consisted of omission of primary antisera.  
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RESULTS: 
 
Levels of SMDR2 RNA increase transiently in adult males in response to sub-lethal 
concentrations of PZQ 
  Adult S. mansoni in culture were exposed to a sublethal concentration of PZQ (100 
nM) for 3h. Total RNA was extracted from these parasites, as well as controls, and reverse-
transcribed into cDNA using random hexamers as primers. Initially, we found that a mixed-
sex population of worms treated with PZQ showed increased levels of SMDR2 RNA as 
determined by RT-PCR. Further experiments in which male and female worms were separated 
prior to PZQ exposure showed that the increase in SMDR2 RNA levels is occurring only in 
males (Fig. 1). Real-time RT-PCR analysis shows a significant 3.37 ± 0.35-fold increase in 
SMDR2 expression in males following 3 h PZQ exposure. However, by 24 h, SMDR2 mRNA 
expression levels have returned to baseline levels (relative SMDR2 expression = 0.88 ± 0.14). 
We also typically see 2-5-fold higher SMDR2 RNA levels in control females (ie, incubated in 
RPMI medium without PZQ) compared to males, consistent with earlier observations by 
others [22]. For example, relative SMDR2 RNA levels are 3.0 ± 0.43-fold higher in 3h control 
female worms than in 3h control males (n = 4). There is also some indication of an increase in 
relative SMDR2 mRNA expression following a 48-h PZQ exposure, although the change is 
not significant (1.83 ± 0.66). Interestingly, a mixed-sex population of adults appears to show 
higher relative levels of SMDR2 RNA following 6 days in 100 nM PZQ (2.81-fold). 
However, as the elimination half-life of PZQ and its metabolites is on the order of hours [34], 
the relevance of any such long-term effects in actual treatment regimens is not clear.  
 Adult males exposed to different concentrations of PZQ show increased SMDR2 
mRNA expression at 3 h, as measured by quantitative RT-PCR. Thus, at 300 nM PZQ, 
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SMDR2 mRNA expression increases 2.17-fold, while 500 nM PZQ results in a 5.6-fold 
increase. As with 100 nM PZQ, the increase is transient. After exposure to 300 nM PZQ for 
24 h, the ratio of SMDR2 mRNA expression compared to controls is 0.6. The level of 
expression following 24 h exposure to 500 nM PZQ could not be measured accurately due to 
excessive worm lethality. We have not yet determined a minimal PZQ concentration that can 
produce the transient increase in SMDR2 mRNA expression. 
Levels of an S. mansoni anti-Pgp immunoreactive protein increase in males in response to 
PZQ. 
 We have used western blots to measure relative levels of schistosome SMDR2 protein 
(or a cross-reacting Pgp-like protein species). For these experiments, we used a monoclonal 
antibody against mammalian Pgp [29]. This antibody targets two Pgp epitopes that are largely 
conserved in the SMDR2 sequence: VQAALD at the N-terminus (VQGALD in SMDR2); and 
VQEALD at the C-terminus (VQKALD in SMDR2). The anti-Pgp antibody detects a single, 
cross-reacting ~140 kDa band in protein extracts from adult S. mansoni (Figs. 2, 5), and 
detects SMDR2 recombinant protein (~140 kDa) expressed in mammalian cells (Kasinathan 
and Greenberg, unpublished results). Exposure of adult male schistosomes to 100 nM PZQ for 
24 hours in culture results in an increase in relative levels of the Pgp-immunoreactive band 
compared to control adult male worms (Fig. 2). Average Pgp band intensity (relative to β-
tubulin) increases 1.92 ± 0.57-fold (n = 5; P = 0.024, paired t-test). We sometimes see evidence 
for an increase in band intensity in females as well, though the change is not significant. Tubulin 
levels did not increase in response to PZQ. Interestingly, additional, anti-Pgp-immunoreactive 
bands of slightly lower molecular weight are sometimes apparent in these experiments 
following PZQ exposure, in both males and females (Fig. 2). An increase is also apparent in 
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male worms exposed to PZQ for 48 h, though to a lesser extent,  and no detectable changes in 
expression levels of anti-Pgp immunoreactivity are observed in S. mansoni exposed to PZQ for 
either 15 min or 3 h (data not shown). Interestingly, the higher level of SMDR2 RNA found in 
females does not appear to be reflected at the protein level, as there is no significant 
difference in relative band intensity (compared to β-tubulin) between control males and 
females. 
 Immunohistochemical labeling was used to localize changes in schistosome anti-Pgp 
immunoreactivity in whole mounts of adult schistosomes. Adult S. mansoni males exposed to 
100 nM PZQ for 18 h showed prominent anti-Pgp immunoreactivity within the gut (Fig. 3A) and 
this labeling was also present surrounding the gut (Fig. 3D). This immunoreactivity was not 
detected in untreated control worms (Fig. 3B), nor in samples not incubated with the primary 
antibody (Fig. 3C).  
SMDR2 RNA and an anti-Pgp-immunoreactive protein are expressed at higher levels  in a 
schistosome isolate with reduced PZQ susceptibility. 
  We examined the expression levels of S. mansoni SMDR2 RNA and anti-Pgp 
immunoreactive protein in adult EE2 and CD1 schistosomes. EE2 is an Egyptian isolate with 
reduced susceptibility to PZQ, while CD1 is a PZQ-sensitive isolate that has never been exposed 
to PZQ [38]. Semiquantitative RT-PCR indicates that SMDR2 RNA is expressed at higher levels 
in  the EE2 worms  (Fig. 4a). In contrast, 18S ribosomal RNA levels in EE2 and CD1 worms are 
relatively constant. Based on quantitation of band intensity and normalization to 18S band 
intensity, SMDR2 RNA is expressed at a 2.68 ± 0.75 fold higher level in EE2 worms compared 
with CD1 worms (P = 0.013, two-tailed t-test, n=5). SMDR2 RNA is also expressed at higher 
levels in EE2 worms than in adult worms from the NMRI strain of S. mansoni. Quantitation of 
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band intensity, with normalization to 18S band intensity, indicates SMDR2 RNA is expressed at 
a 2.92-fold higher level in EE2 adults than in NMRI worms. 
       We also tested relative SMDR2 RNA levels using real time quantitative PCR (Fig. 4b). In 
this case, highly representative, amplified cDNA samples [33] made from EE2 and CD1 
schistosomes were used as templates. These types of cDNA samples have been verified by others 
to be accurate reflections of differential gene expression [34]. From these experiments, we 
determined that the normalized expression ratio of SMDR2 RNA, using GAPDH as the reference 
sequence, is 12.4 in the EE2 isolate compared to the CD1 isolate.  
 Anti-Pgp immunoreactive protein is also expressed at higher levels in the EE2 
isolate (Fig. 5). In contrast, levels of β-tubulin are equivalent in EE2 and CD1 worms. 
This increased level of putative Pgp expression has been observed in four separate blots. 
Schistosome anti-Pgp immunoreactivity is also higher in EE2 adults compared to adult 
worms from the NMRI strain of S. mansoni (data not shown). 
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DISCUSSION:  
 Multidrug resistance was originally characterized in mammalian tumor cells that 
had been selected for resistance to a single drug, but which also showed an unpredictable 
cross-resistance against several structurally unrelated compounds. A major mediator of 
this effect is Pgp, an ATP-dependent transporter that functions to remove toxic and 
xenobiotic compounds from cells. Alterations of Pgp expression levels and allele 
frequencies have also been implicated in drug resistance in various parasites, including 
helminths [17, 18]. We have demonstrated in this report that treatment of schistosomes 
with sublethal PZQ concentrations in vitro results in an apparently transient increase in 
SMDR2 RNA and anti-Pgp immunoreactive protein in adult male parasites. Increases in 
SMDR2 protein levels are not coincident with the increase in SMDR2 mRNA, indicating 
a delay between transcription of SMDR2 mRNA and translation and processing of 
SMDR2 protein. Our results also point to higher levels of Pgp being associated with 
reduced susceptibility to PZQ in S. mansoni.  
 It remains to be determined whether this increased Pgp level is involved in the 
mechanism by which PZQ resistance can develop, or is, instead, simply a correlate of this 
process. However, the apparent upregulation of SMDR2 RNA and Pgp protein in adult 
parasites following exposure to PZQ, as well as the recent observation that PZQ is an 
inhibitor of mammalian Pgp [27], indicate that PZQ may be interacting in important ways 
with schistosome Pgp transporters. If PZQ is also an inhibitor, or possibly a substrate, of 
schistosome Pgp, increased Pgp levels might serve as a mechanism by which the parasite 
can escape the effects of standard or reduced doses of PZQ. If PZQ does inhibit 
schistosome Pgp, the worm may respond by increasing Pgp levels to compensate for the 
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deleterious effects of this reduced excretory activity. If, instead, or in addition, PZQ is a 
substrate for Pgp, then upregulated expression of Pgp (and perhaps other drug 
transporters) may help clear the drug from cells. Interestingly, we find that PZQ 
treatment often results in the appearance of a second, slightly lower MW anti-Pgp 
immunoreactive protein on western blots. This band may represent a second cross-
reacting Pgp-like protein, or possibly a differentially modified (eg, glycosylated) form 
of SMDR2, and may be involved in mediating parasite defenses against PZQ.  
 PZQ is the drug of choice against schistosomiasis and has more recently become 
effectively the sole treatment available for the disease. However, approximately three 
decades following its introduction, a detailed mode of action for PZQ remains elusive, 
and reports of emerging PZQ resistance are a cause of particular concern [7, 39, 40]. One 
strategy for overcoming drug resistance might be to potentiate the effectiveness of current 
drugs by including additional agents targeted against different, but perhaps interacting, 
sites of action, or against cellular components, such as Pgp, that regulate rates of drug 
efflux. Indeed, PZQ has been shown to affect excretion of Pgp substrates in schistosomes 
[26], perhaps a functional correlate of the effects we see on Pgp expression. Although 
investigation of the effects of higher, more clinically relevant PZQ concentrations (eg, 
≥500 nM) on Pgp expression would have been interesting, those concentrations result 
in significant worm lethality over the extended periods examined in these experiments. 
In this study, we were particularly interested in examining the effects on adult worms 
of exposure to sublethal concentrations of PZQ in order to begin the dissection of the 
physiological responses of schistosomes to PZQ, and also the possible mechanisms by 
which PZQ resistance might develop. Further experiments examining parasite 
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responses within the host should be particularly informative in this regard. Additional 
experiments on other worm stages that are less susceptible to PZQ, as well as a more 
detailed examination of SMDR2 levels in various schistosome isolates with lower 
sensitivity to PZQ may help define the role these transporters might play in reduced 
drug susceptibility. It will also be interesting to determine effects of PZQ on other 
schistosome drug and xenobiotic transporters (eg, multidrug resistance-like proteins) 
and interacting proteins, and whether other Pgp substrates and inhibitors potentiate or 
reduce PZQ antischistosomal activity. 
 In this study, we have investigated the effects of PZQ on S. mansoni SMDR2 
expression. However, the functional and pharmacological properties of SMDR2 and other 
schistosome drug transporters remain to be determined. Direct functional assays of 
schistosome drug transporters, along with genetic manipulation, may provide more 
complete information about the interplay of PZQ and these proteins, and may also 
provide clues for development of novel anthelmintics.   
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FIGURE LEGENDS: 
Figure 1. Exposure of adult males to PZQ results in increased SMDR2 RNA expression. 
Real time RT-PCR on S. mansoni adult males and females treated with 100 nM PZQ  in vitro for 
3 hours, 24 hours, or 48 hours using primers to SMDR2 and GAPDH. The 2-ΔΔCt method [32] 
was used to determine the relative expression ratio between SMDR2 and GAPDH mRNAs. 
Asterisk indicates a statistically significant difference from a value of 1, which would indicate no 
change (one sample t-test, P = 0.001). 
Figure 2.  Exposure of adult male schistosomes to PZQ results in increased levels of Pgp-
immunoreactive protein. Proteins were extracted from S. mansoni adult males and females 
following treatment of worms in vitro with 100 nM PZQ (+) or parallel controls (-) for 24 h. 
Proteins were electrophoresed and immunoblotted as described in Materials and Methods. Bars 
on left are molecular weight markers, from top, 160 kDa and 110 kDa. Primary antibodies were 
against conserved Pgp epitopes (Pgp) or against β-tubulin.  
Figure 3. PZQ exposure increases anti-Pgp immunoreactivity in adult worms. 
Immunostaining using the monoclonal antibody to conserved Pgp epitopes shows positive Pgp-
like immunoreactivity in the gut of worms exposed to 100 nM PZQ for 18 h (A, arrow), which is 
not present in control schistosomes (B), or in worms incubated with secondary antibody alone 
(C). Black material in the gut in (B) is likely digested hemoglobin. Immunoreactivity also 
appears in the epithelial layer surrounding the gut (D, arrow). The thick black line (A) is an 
artifact, and the faint surface staining in control worms (B) appears inconsistently, and is likely 
also artifactual. A-C, scale bar = 60 μm, D, scale bar = 20 μm.  
Figure 4. SMDR2 RNA transcript is expressed at higher levels in an isolate of S. mansoni 
with reduced PZQ susceptibility. (A) RT-PCR amplification (35 cycles) of SMDR2 or 18S 
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ribosomal RNA from adult parasites of the PZQ-sensitive CD1 isolate (CD), or the EE2 isolate, 
which has reduced sensitivity to PZQ. (B) Real-time RT-PCR amplification curves for SMDR2 
and GAPDH cDNA pools from CD1 and EE2 isolates. Source of template and identity of 
amplified sequence are denoted on the plot. 
 
Figure 5. Expression of a Pgp-immunoreactive protein expression is higher in a S. mansoni 
isolate with reduced susceptibility to PZQ. Proteins were extracted from S. mansoni CD1 and 
EE2 adults. Proteins were electrophoresed and immunoblotted as described in Materials and 
Methods. Primary antibodies were against conserved  Pgp epitopes (Pgp) or against β-tubulin 
(Tubulin). Lines at right of image designate size markers. Top line = 188 kDa; middle line = 97 
kDa; bottom line = 52 kDa.  
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